Get answers to some of the most common questions about TRUQAP below.
As with many treatments for metastatic breast cancer, before you start TRUQAP, your doctor may test for different biomarkers. Biomarkers can show if there are abnormal changes called tumor mutations or alterations. TRUQAP works in people whose cancer has biomarker testing that shows abnormal changes in PIK3CA, AKT1, and/or PTEN genes—and whose disease has progressed on or after hormone therapy.
If you haven’t been tested for biomarkers yet, you can still be tested at any time. Be sure to ask your doctor about biomarker testing.
In people with HR+/HER2– metastatic breast cancer with abnormal PIK3CA, AKT1, and/or PTEN genes, overactive signaling in cancer cells can make the tumor grow. TRUQAP is an AKT inhibitor that works by disrupting signals from the AKT protein and other proteins along its pathway that can drive cancer growth.
TRUQAP is taken with the hormone therapy, fulvestrant. Fulvestrant works by disrupting signals from the hormone estrogen that fuel tumor growth.
Learn more about how TRUQAP works.
TRUQAP is taken 4 days in a row, followed by 3 days not taking TRUQAP, each week.


TRUQAP is available in a blister pack for select doses.
The recommended starting dosage of TRUQAP is 400 mg two times each day for a total daily dose of 800 mg.
Take TRUQAP exactly as your doctor tells you to, as your doctor may adjust your dose. Do not change your dose or stop taking TRUQAP unless your doctor tells you to.
Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. TRUQAP may affect the way other medicines work, and other medicines may affect how TRUQAP works.
Know the medicines you take. Keep a list of them to show your doctor, nurse, or pharmacist when you get a new medicine.
Learn more about how to take TRUQAP.
Store TRUQAP in original packaging at room temperature between 68 °F to 77 °F (20 °C to 25 °C).
Throw away (discard) TRUQAP after 45 days if the tablets are not kept in the original packaging.
TRUQAP comes in child-resistant packaging.
If you miss a dose of TRUQAP, you may still take it within 4 hours from the time you usually take it. If it has been more than 4 hours after you usually take your dose, skip that dose. Take the next dose at your usual time. Do not take two doses at once to make up for a missed dose.
Learn more about how to take TRUQAP.
TRUQAP may cause severe side effects, including:
The most common side effects of TRUQAP are:
Remember to always tell your doctor about any side effects you experience, especially if side effects are severe, don’t go away, or get worse.
These are not all of the possible side effects of TRUQAP. For more information, ask your doctor, nurse, or pharmacist. Please see full Important Safety Information below.
You may report side effects related to AstraZeneca products.
You may experience side effects at any time during your TRUQAP treatment. Side effects can be challenging, but sometimes you and your healthcare team can do things to help you manage them. Always take TRUQAP + fulvestrant exactly as your doctor tells you to, and do not stop your dose unless your doctor tells you to.
If side effects are interfering with your life, your doctor may:
Some side effects may be managed with your doctor’s help. See tips for side effect management.
TRUQAP is taken as a combination therapy, which means it's intended to work with another medicine so that you can get the best results.
TRUQAP works with the hormone therapy fulvestrant. Fulvestrant is an injectable hormone therapy that your doctor will administer on a specific schedule. Each dose of fulvestrant is 500 mg.
Your doctor will follow the recommended fulvestrant dosing information in the fulvestrant Prescribing Information.
Progression-free survival is the amount of time that your cancer doesn’t grow or spread while you’re on therapy.
TRUQAP + fulvestrant is proven to give people with HR+/HER2- metastatic breast cancer with abnormal PIK3CA, AKT1, and/or PTEN genes more than twice as long without their cancer growing or spreading compared with the hormone therapy fulvestrant alone. This is called progression-free survival.
MORE
THAN
2X
LONGER WITHOUT TUMOR GROWTH
TRUQAP + fulvestrant delivered an average of 7.3 months vs 3.1 months with fulvestrant alone—a difference of 4.2 months.*
Results may vary.
The trial showed no significant difference in how long patients lived between treatment groups.
*Median time from the start of treatment that patients’ tumors did not grow or spread. Median is the middle number in a group of numbers listed from lowest to highest.
Learn more about these clinical trial results.
AstraZeneca may be able to help you access the medicine you need. To find out more, visit www.MyAccess360.com or call 1-844-ASK-A360 (1-844-275-23601-844-275-2360).
You can also sign up for the MyTRUQAP Support Program to stay in the know about TRUQAP and receive co-pay assistance and helpful resources.
Discover ways care partners can help
Care partner supportJoin our patient support program
MyTRUQAP Support ProgramAKT=serine/threonine protein kinase; AKT1=serine/threonine=serine/ threonine protein kinase 1; HER2–=human epidermal growth factor receptor 2 negative; HR+=hormone receptor positive; PIK3CA=phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; PTEN=phosphatase and tensin homolog.
Important Safety Information about TRUQAP® (capivasertib) tablets
ExpandDo not take TRUQAP if you have had a severe allergic reaction to TRUQAP or are allergic to any of the ingredients of TRUQAP.
Before you take TRUQAP, tell your healthcare provider about all your medical conditions, including if you:
Females who are able to become pregnant:
Males with female partners who are able to become pregnant should use effective birth control during your treatment with TRUQAP and for 4 months after the last dose. If your female partner becomes pregnant, tell your healthcare provider right away.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. TRUQAP may affect the way other medicines work, and other medicines may affect how TRUQAP works. Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine.
TRUQAP may cause severe side effects, including:
Your healthcare provider may tell you to decrease your dose, temporarily stop your treatment, or completely stop your treatment with TRUQAP if you get certain serious side effects.
The most common side effects of TRUQAP include nausea, tiredness, vomiting, mouth sores and changes in certain blood tests.
These are not all the possible side effects of TRUQAP. Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
TRUQAP is a prescription oral medicine used in combination with the medicine fulvestrant to treat adults who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that is advanced or that has spread to other parts of the body (metastatic), with an abnormal “PIK3CA”, “AKT1”, or “PTEN” gene, and whose disease has progressed on or after endocrine therapy.
Your healthcare provider will test your cancer for an abnormal “PIK3CA”, “AKT1”, or “PTEN” gene to make sure that TRUQAP is right for you.
It is not known if TRUQAP is safe and effective in children.
Please see full Prescribing Information, including Patient Information for TRUQAP.
You may report side effects related to AstraZeneca products.